MediciNova (MNOV) Stock Forecast & Price Target $1.37 -0.02 (-1.44%) Closing price 04:00 PM EasternExtended Trading$1.37 +0.00 (+0.29%) As of 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MediciNova - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating Moderate BuyBased on 7 Analyst RatingsSell1Hold1Buy5 Based on 7 Wall Street analysts who have issued ratings for MediciNova in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 7 analysts, 1 has given a sell rating, 1 has given a hold rating, 3 have given a buy rating, and 2 have given a strong buy rating for MNOV. Consensus Price Target $7.50447.45% Upside According to the 7 analysts' twelve-month price targets for MediciNova, the average price target is $7.50. The highest price target for MNOV is $10.00, while the lowest price target for MNOV is $5.00. The average price target represents a forecasted upside of 447.45% from the current price of $1.37. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for MNOV and Related Stocks Enter your email address to receive the latest news and analysts' ratings for MediciNova and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MNOV Analyst Ratings Over TimeTypeCurrent Forecast5/21/25 to 5/21/261 Month Ago4/21/25 to 4/21/263 Months Ago2/20/25 to 2/20/261 Year Ago5/21/24 to 5/21/25Strong Buy2 Strong Buy rating(s)2 Strong Buy rating(s)2 Strong Buy rating(s)0 Strong Buy rating(s)Buy3 Buy rating(s)3 Buy rating(s)1 Buy rating(s)1 Buy rating(s)Hold1 Hold rating(s)1 Hold rating(s)1 Hold rating(s)0 Hold rating(s)Sell1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)0 Sell rating(s)Consensus Price Target$7.50$7.50$7.00$9.00Forecasted Upside447.45% Upside428.17% Upside366.67% Upside547.48% UpsideConsensus RatingModerate BuyModerate BuyModerate BuyBuy MNOV Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History MNOV Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table MediciNova Stock vs. The CompetitionTypeMediciNovaMedical CompaniesBroader MarketConsensus Rating Score 2.86 2.29 2.52Consensus RatingModerate BuyHoldModerate BuyPredicted Upside447.45% Upside1,714.86% Upside16.00% UpsideNews Sentiment RatingVery Positive NewsSee Recent MNOV NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails5/4/2026 D. Boral Capital3 of 5 starsJason Kolbert3 of 5 starsReiterated RatingBuy$9.00+540.11%3/27/2026 Weiss RatingsNot Rated Reiterated RatingSell (D-)3/23/2026 Maxim Group1 of 5 starsJason McCarthy1 of 5 starsReiterated RatingBuy$6.00+284.61%3/17/2026 Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeHold3/16/2026 HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLander EgañaSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageBuy$10.00+640.74%1/5/2026 Lucid Cap MktsSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeStrong-Buy6/16/2025 B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMayank MamtaniSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeBuy ➝ Strong-Buy$6.00 ➝ $5.00+281.68%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 11:46 PM ET. MNOV Forecast - Frequently Asked Questions What is MediciNova's forecast for 2026? According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for MediciNova is $7.50, with a high forecast of $10.00 and a low forecast of $5.00. Should I buy or sell MediciNova stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There is currently 1 sell rating, 1 hold rating, 3 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MNOV shares. Does MediciNova's stock price have much upside? According to analysts, MediciNova's stock has a predicted upside of 447.45% based on their 12-month stock forecasts. Has MediciNova been upgraded by Wall Street analysts recently? Over the previous 90 days, MediciNova's stock had 1 upgrade by analysts. What analysts cover MediciNova? MediciNova has been rated by research analysts at D. Boral Capital, HC Wainwright, Maxim Group, Weiss Ratings, and Zacks Research in the past 90 days. Do Wall Street analysts like MediciNova more than its competitors? Analysts like MediciNova more than other "medical" companies. The consensus rating for MediciNova is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how MNOV compares to other companies. Stock Forecasts and Research Tools Related Companies Entrada Therapeutics Stock Forecast Compugen Stock Forecast Inhibikase Therapeutics Stock Forecast Cybin Stock Forecast Minerva Neurosciences Stock Forecast Artiva Biotherapeutics Stock Forecast Foghorn Therapeutics Stock Forecast Fate Therapeutics Stock Forecast Cartesian Therapeutics Stock Forecast Sagimet Biosciences Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With MediciNova RecommendationsD. Boral CapitalWeiss RatingsMaxim GroupZacks ResearchHC WainwrightLucid Cap MktsB. Riley Financial This page (NASDAQ:MNOV) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediciNova, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediciNova With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
